Mark Roschewski

9.4k total citations
131 papers, 2.9k citations indexed

About

Mark Roschewski is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Mark Roschewski has authored 131 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pathology and Forensic Medicine, 59 papers in Oncology and 46 papers in Genetics. Recurrent topics in Mark Roschewski's work include Lymphoma Diagnosis and Treatment (90 papers), Chronic Lymphocytic Leukemia Research (41 papers) and CAR-T cell therapy research (32 papers). Mark Roschewski is often cited by papers focused on Lymphoma Diagnosis and Treatment (90 papers), Chronic Lymphocytic Leukemia Research (41 papers) and CAR-T cell therapy research (32 papers). Mark Roschewski collaborates with scholars based in United States, United Kingdom and Switzerland. Mark Roschewski's co-authors include Wyndham H. Wilson, Louis M. Staudt, Kieron Dunleavy, Stefania Pittaluga, Elaine S. Jaffe, Seth M. Steinberg, Christopher Melani, Margaret Shovlin, Ola Landgren and Neha Korde and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Mark Roschewski

121 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Roschewski United States 25 1.4k 1.3k 779 627 549 131 2.9k
Loïc Ysebaert France 33 1.7k 1.2× 1.5k 1.1× 804 1.0× 1.1k 1.8× 208 0.4× 139 3.7k
Barrett H. Childs United States 20 731 0.5× 2.1k 1.6× 572 0.7× 334 0.5× 567 1.0× 101 3.3k
Catherine Spier United States 30 1.8k 1.3× 2.0k 1.5× 857 1.1× 671 1.1× 143 0.3× 73 3.6k
G.J. Ossenkoppele Netherlands 34 812 0.6× 1.1k 0.8× 783 1.0× 677 1.1× 256 0.5× 84 3.3k
Alejandro Martı́n Spain 25 861 0.6× 1.4k 1.0× 845 1.1× 533 0.9× 154 0.3× 128 2.8k
Brian T. Hill United States 27 962 0.7× 1.2k 0.9× 746 1.0× 790 1.3× 115 0.2× 225 2.7k
Sergej Konoplev United States 35 964 0.7× 1.4k 1.0× 1.4k 1.8× 1.2k 2.0× 452 0.8× 154 4.6k
Stephen Opat Australia 25 1.7k 1.2× 980 0.7× 446 0.6× 1.4k 2.2× 135 0.2× 158 2.7k
J Garcı́a-Conde Spain 35 1.1k 0.8× 2.0k 1.5× 954 1.2× 792 1.3× 584 1.1× 104 3.9k
Julio Delgado Spain 35 1.3k 0.9× 1.0k 0.8× 647 0.8× 1.6k 2.6× 171 0.3× 195 3.6k

Countries citing papers authored by Mark Roschewski

Since Specialization
Citations

This map shows the geographic impact of Mark Roschewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Roschewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Roschewski more than expected).

Fields of papers citing papers by Mark Roschewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Roschewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Roschewski. The network helps show where Mark Roschewski may publish in the future.

Co-authorship network of co-authors of Mark Roschewski

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Roschewski. A scholar is included among the top collaborators of Mark Roschewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Roschewski. Mark Roschewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2025). Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Journal of Clinical Oncology. 43(34). 3652–3661.
2.
Hercun, Julian, et al.. (2025). Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent. Liver International. 45(3). e70022–e70022.
3.
Goldstein, Jordan, Mark Roschewski, Won-Seog Kim, et al.. (2024). Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL. Blood. 144(Supplement 1). 651–651.
4.
Melani, Christopher, Max J. Gordon, Stefania Pittaluga, et al.. (2024). Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies. Blood Cancer Discovery. 5(3_Supplement). PO–8.
5.
Matasar, Matthew J., Marcus Messmer, Rashmi Khanal, et al.. (2024). Abstract CT245: Circulating tumor DNA and nivolumab maintenance: A pilot study in diffuse large B cell lymphoma. Cancer Research. 84(7_Supplement). CT245–CT245.
6.
Asch, Adam S., Leslie Popplewell, Graham P. Collins, et al.. (2024). Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 8(22). 5864–5874. 6 indexed citations
7.
Mehta, Amitkumar, Leslie Popplewell, Graham P. Collins, et al.. (2024). Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial. Blood Advances. 8(22). 5855–5863. 13 indexed citations
8.
Dalela, D., Stefania Pittaluga, Jagan Muppidi, et al.. (2023). IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL). Clinical Lymphoma Myeloma & Leukemia. 23. S451–S451. 1 indexed citations
9.
Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2023). MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS. Hematological Oncology. 41(S2). 177–179. 5 indexed citations
10.
Roschewski, Mark, Manish R. Patel, Patrick M. Reagan, et al.. (2023). Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical Cancer Research. 29(17). 3301–3312. 13 indexed citations
11.
López, Cristina, Birgit Burkhardt, John K. C. Chan, et al.. (2022). Burkitt lymphoma. Nature Reviews Disease Primers. 8(1). 78–78. 55 indexed citations
12.
Pittaluga, Stefania, Jagan Muppidi, James D. Phelan, et al.. (2021). Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. Blood. 138(Supplement 1). 4504–4504. 8 indexed citations
13.
Holdhoff, Matthias, Nina D. Wagner‐Johnston, & Mark Roschewski. (2020). Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. SHILAP Revista de lepidopterología. 1 indexed citations
14.
Ahlman, Mark A., Christopher Melani, Stefania Pittaluga, et al.. (2019). Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR. Blood. 134(Supplement_1). 4080–4080.
15.
Melani, Christopher, Mark Roschewski, Stefania Pittaluga, et al.. (2018). Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis. Blood. 132(Supplement 1). 785–785. 3 indexed citations
16.
Mailankody, Sham, Neha Korde, Elisabet E. Manasanch, et al.. (2017). Host-related immunodeficiency in the development of multiple myeloma. Leukemia & lymphoma. 59(5). 1127–1132. 14 indexed citations
17.
Saba, Nakhle S., Delong Liu, Sarah E. M. Herman, et al.. (2016). Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 128(1). 82–92. 111 indexed citations
18.
Sun, Ellen X., Mark Roschewski, Georg Aue, et al.. (2012). ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress. Clinical Cancer Research. 18(7). 1979–1991. 61 indexed citations
19.
20.
Shapeero, Lorraine G., et al.. (2010). Multiple myeloma with lacrimal gland amyloidosis and sarcoidosis. American Journal of Hematology. 85(7). 506–509. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Loïc Ysebaert Breakdown of academic impact, for papers by Barrett H. Childs Breakdown of academic impact, for papers by Catherine Spier Breakdown of academic impact, for papers by G.J. Ossenkoppele Breakdown of academic impact, for papers by Alejandro Martı́n Breakdown of academic impact, for papers by Brian T. Hill Breakdown of academic impact, for papers by Sergej Konoplev Breakdown of academic impact, for papers by Stephen Opat Breakdown of academic impact, for papers by J Garcı́a-Conde Breakdown of academic impact, for papers by Julio Delgado
Rankless by CCL
2026